ArticleOncotarget2017
Statin use and endometrial cancer risk: a meta-analysis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022Pooled it
- Global trends, knowledge structure, and thematic evolution of statin-cancer research: A comprehensive mapping and visualization study with insights from highly cited literature (1940-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Obesity-Related Cancers in Relation to Use of Statins and Testosterone Replacement Therapy Among Older Women: SEER-Medicare 2007-2015.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Simvastatin inhibits the immunosuppressive effects of endometrial cancer-associated mesenchymal stem cells through TGF-β2/SMAD2/3 signaling and reduces tumor growth.Scientific reports · 2025Article
- Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.Journal of clinical medicine · 2025Review
- The Role of Statins in the Prevention of Ovarian and Endometrial Cancers.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Lipid-lowering medication use and cancer-specific survival among endometrial or lung cancer patients: an Australian nationwide cohort study.European journal of clinical pharmacology · 2021Article
- Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Beyond lipid-lowering: role of statins in endometrial cancer.Molecular biology reports · 2020Review
- Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis.Journal of clinical medicine · 2019Article
- Melatonin May Increase Anticancer Potential of Pleiotropic Drugs.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have evaluated the association between statin use and endometrial cancer risk. We carried out a meta-analysis of randomized controlled trials (RCTs) and non-randomized studies to evaluate the effect of statins on endometrial cancer risk. A comprehensive search of electronic databases, conference abstracts and clinical trial registers was conducted for published and unpublished results. Studies that evaluated exposure to statins and endometrial cancer risk were considered. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using either a fixed-effects or a random-effects model. Two RCTs and eleven non-randomized studies (four cohort and seven case-control studies) involving 9,517 cases of endometrial cancer were included in the analysis. There was no evidence of an association between statin use and endometrial cancer risk either among RCTs (RR, 0.72; 95% CI, 0.19 to 2.67) or among non-randomized studies (RR, 0.94; 95% CI, 0.82 to 1.07). Combined analysis of all included studies also showed that statin use did not significantly affect endometrial cancer risk (RR, 0.94; 95% CI, 0.82 to 1.07). The sensitivity analysis confirmed the stability of our results. Our findings do not support a protective effect of statins against endometrial cancer at the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.